The ability of PHD inhibitors to increase hemoglobin levels can also be useful in the context of cancer by treating ischemic damage, modulating cellular metabolism, increasing levels of EPO, and increasing sensitivity to chemo- and radiotherapy [187]. The gene discussed is PDC; the disease is cancer.